We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 164.80 | 164.80 | 165.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/3/2017 16:24 | Gotta wonder what all that dumping to go sub 130p was all about........ | soundbuy | |
21/3/2017 14:35 | Pawdaw-exactly my sentiments. I'm now keeping my fingers crossed for May 10th, probably the most significant day of the year for VEC. | alexchry | |
21/3/2017 14:11 | As a former skp holder I'm happy with today's results and pleased to see the share price return to levels associated with the take-over, sorry merger. Enough to make me breathe easy for now. | pawdaw | |
21/3/2017 13:57 | pooroldboy, we didn't have a single afternoon reversal whilst you were on holiday ;-) | popper joe | |
21/3/2017 13:49 | like SKP hang on in compared to SKP this is fun | pooroldboy55 | |
21/3/2017 13:44 | Poorold-yes we can. Tedium-a lot of PIs have no real patience and sell out irrespective of co prospects-same kind as sold at 128 a few weeks back. This is a growth company in a growth area but quick returns no. However medium to long term they are the road to riches. imo | cumnor | |
21/3/2017 13:12 | Must be due one or two broker updates in light of results exceeding Numis' numbers | cap160 | |
21/3/2017 12:43 | God we cant go red today can we!!!!!!!!!!!!!!!!! | pooroldboy55 | |
21/3/2017 12:23 | good results and moving in the right direction... I particulary like the fact 80% of revenue is now recurring.. moves away from dependancy on milestone payments... | sikhthetech | |
21/3/2017 12:09 | Also happy, will poss sell some next financial year as used up my cap gains for tax year. | pooroldboy55 | |
21/3/2017 10:52 | No soundboy, very pleased with this. Solid company that's actually growing and making money and things. Generic advair will be a nice boost later this year. Not too bothered about GSK litigation as the company has too many other growth prospects, esp from 2020 on. | cumnor | |
21/3/2017 10:48 | Quiet board considering.......pu Hmmmm...... | soundbuy | |
21/3/2017 09:07 | All reads well...... :) | soundbuy | |
21/3/2017 08:54 | Well the market is liking this!Maybe back to previous highs sooner than we think.. | gswredland | |
21/3/2017 08:25 | You know who you are! ? | richtea1701 | |
21/3/2017 08:24 | Are the resident pessimists a little happier now? | richtea1701 | |
21/3/2017 08:00 | 'The COPD study in China did successfully achieve its primary endpoints.' This is surprising and positive. Flutiform is a success story and with the approval of a new breath triggered inhaler (K-Haler) it will continue. This will be the first breath-triggered inhaler in the Asthma market using a combination product. And because coordination between activation and inhalation with this kind of MDI is a serious problem for many patients the K-Haler will have a very positive impact. Looking forward to this approval and launch. Also very positive the first launch of the 'handheld smart nebuliser FOX® technology (branded as BreelibTM) used by the Group's partner, Bayer' ! | chop55 | |
21/3/2017 07:15 | 'Transformational' will be the bit market likes hopefully. | richtea1701 | |
21/3/2017 07:13 | Very good results. James W-L says: "With its proven formulation, device and development capabilities Vectura is well-positioned to accelerate shareholder value creation, capitalising on changes in the market dynamics of the inhaled respiratory market. | verger | |
20/3/2017 22:27 | There should be a lot of potential here for those with (still more) patience. However, given the rise in the weeks before results, profit taking is likely and a corresponding dip unless results and statement of early prospects surprise to the upside. Any unresolved or new negative issues could greatly exaggerate any dip giving a chance to those looking for a good entry point. | boadicea | |
20/3/2017 11:32 | We need a good increase in ebitda day to get the P/E ratio down. | fhmktg | |
20/3/2017 10:12 | Looks like a very positive view of results is in the market, hope we are not disappointed, not expecting anything significant but happy to be surprised... | diesel |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions